Galderma to Showcase Latest Updates From Its Broad, Innovative and Leading Dermatology Portfolio at the 2024 American Academy of Dermatology Annual Meeting
Galderma will present two late-breaking presentations on clinical trials evaluating the long-term efficacy of the investigational monoclonal antibody nemolizumab in prurigo nodularis and its durability in atopic dermatitis1,2 Five oral posters and 16 e-posters



